Harnessing the microbiome
to improve health
Osel, Inc. is pioneering a new class of medicine called Live Biotherapeutic Products that modulate the body’s natural microbiome to restore health and prevent infection.
Osel was featured in the September issue of Chemistry & Industry Magazine, a publication of the UK Society of Chemical Industry (SCI), for an article focusing on the role of the healthy vaginal microbiome in women’s health. The article covers the launch of our Phase 2b trial for LACTIN-V, a live biotherapeutic, as well as a recent study presented at the International AIDS 2016 Conference that found that an overgrowth of certain bacteria in the vagina was associated with both higher transmission of HIV and reduced efficacy of an anti-HIV drug – and highlighted the importance of a healthy vaginal microbiome in preventing the transmission of HIV.read more
MOUNTAIN VIEW, CA (July 21, 2016): Osel, Inc. today commented on findings presented by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers at the International AIDS 2016 Conference, detailing the role played by vaginal dysbiosis in the high rates of sexual transmission of HIV to women from men.read more
Osel, Inc.’s Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis
Mountain View, CA (May 11, 2016): Osel, Inc. today announced the initiation of a Phase 2b clinical study of its lead product candidate, LACTIN-V, to prevent the recurrence of bacterial vaginosis following antibiotic therapy.read more